Risk Evaluation and Mitigation Strategies [REMS] Program Con

A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy.

NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.

Related Keywords

Florida , United States , Bryan Cain , Ryan Haumschild , Kirollos Hanna , Sarah Rockwell , Peer Exchange , Melody Chang , Risk Evaluation , Mitigation Strategy , Florida Cancer Specialists , Bispecifics , Local Treatment Centers , Krems , Operational Pressures , Compliance , Hospitalization , Hospitalization Protocol , Bispecific , Bispecific Antibodies , Teclistamab , Talquetamab , Fda Approval , Authorized Representative , Clinical Nurse Managers , Certification , Provider Documentation , Injection , Wallet Card , Adverse Effect , Emergency Room , Therapy Toxicities , Cytokine Release Syndrome , Crs , Risk Evaluation Mitigation Strategies , Outpatient , Inpatient , Risk Stratification , Drg Reimbursement , Diagnose Related Group , Average Sales Price , Financial Considerations , Community Practices , Emr Integration ,